Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSBR NASDAQ:NERV NASDAQ:PRLD NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.98+0.2%$5.96$5.50▼$9.63$82.90M0.427,070 shs17,919 shsNERVMinerva Neurosciences$6.23-0.3%$6.52$1.30▼$12.46$274.01M-0.08189,040 shs87,908 shsPRLDPrelude Therapeutics$4.84+3.6%$3.73$0.75▼$5.54$294.22M1.11547,105 shs708,102 shsTARAProtara Therapeutics$5.66+4.6%$5.37$2.77▼$7.82$297.88M1.53620,802 shs577,040 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology+0.17%+0.88%-0.83%-9.33%+1.96%NERVMinerva Neurosciences-0.32%-2.50%+19.12%+47.63%+286.96%PRLDPrelude Therapeutics+3.64%+13.35%+31.52%+139.60%+508.04%TARAProtara Therapeutics+4.62%+9.48%+11.64%-12.92%+67.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.98+0.2%$5.96$5.50▼$9.63$82.90M0.427,070 shs17,919 shsNERVMinerva Neurosciences$6.23-0.3%$6.52$1.30▼$12.46$274.01M-0.08189,040 shs87,908 shsPRLDPrelude Therapeutics$4.84+3.6%$3.73$0.75▼$5.54$294.22M1.11547,105 shs708,102 shsTARAProtara Therapeutics$5.66+4.6%$5.37$2.77▼$7.82$297.88M1.53620,802 shs577,040 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology+0.17%+0.88%-0.83%-9.33%+1.96%NERVMinerva Neurosciences-0.32%-2.50%+19.12%+47.63%+286.96%PRLDPrelude Therapeutics+3.64%+13.35%+31.52%+139.60%+508.04%TARAProtara Therapeutics+4.62%+9.48%+11.64%-12.92%+67.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology 1.00SellN/AN/ANERVMinerva Neurosciences 2.00Hold$10.5068.54% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6758.40% UpsideTARAProtara Therapeutics 2.83Moderate Buy$24.75337.28% UpsideCurrent Analyst Ratings BreakdownLatest CSBR, TARA, PRLD, and NERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026NERVMinerva Neurosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$14.003/27/2026NERVMinerva Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/12/2026NERVMinerva Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$4.00 ➝ $7.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$56.94M1.46$0.46 per share13.02$0.27 per share22.15NERVMinerva NeurosciencesN/AN/AN/AN/A($3.25) per shareN/APRLDPrelude Therapeutics$12.14M25.12N/AN/A$1.09 per share4.44TARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/16/2026 (Estimated)NERVMinerva Neurosciences-$293.42M-$26.80N/AN/AN/AN/AN/A-39.18%5/12/2026 (Estimated)PRLDPrelude Therapeutics-$99.50M-$1.29N/AN/AN/AN/A-129.98%-80.85%N/ATARAProtara Therapeutics-$57.44M-$1.32N/AN/AN/AN/A-36.38%-33.81%5/14/2026 (Estimated)Latest CSBR, TARA, PRLD, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TARAProtara Therapeutics-$0.36N/AN/AN/AN/AN/A5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A3/10/2026Q4 2025PRLDPrelude Therapeutics-$0.33-$0.20+$0.13-$0.20$20.50 million$5.64 million3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.980.98NERVMinerva NeurosciencesN/A36.2936.29PRLDPrelude TherapeuticsN/A1.991.99TARAProtara TherapeuticsN/A14.5814.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%NERVMinerva Neurosciences34.56%PRLDPrelude Therapeutics79.72%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology46.98%NERVMinerva Neurosciences10.40%PRLDPrelude Therapeutics63.90%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.89 million7.36 millionOptionableNERVMinerva Neurosciences943.84 million39.28 millionNot OptionablePRLDPrelude Therapeutics12063.00 million22.74 millionOptionableTARAProtara Therapeutics3055.06 million50.44 millionOptionableCSBR, TARA, PRLD, and NERV HeadlinesRecent News About These CompaniesOne Protara Therapeutics Insider Raised Their Stake In The Previous YearMay 4 at 8:39 AM | finance.yahoo.comEquities Analysts Offer Predictions for TARA FY2028 EarningsMay 4 at 1:33 AM | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Price Target Raised to $27.00 at HC WainwrightApril 29, 2026 | marketbeat.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...April 28, 2026 | markets.businessinsider.comProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingApril 27, 2026 | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comStock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA)April 8, 2026 | marketbeat.comJacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) StockApril 3, 2026 | insidertrades.comProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateMarch 10, 2026 | globenewswire.comBladder phase II sinks Protara, LMs phase III wins for PalvellaFebruary 25, 2026 | bioworld.comBProtara reports encouraging phase 2 results for TARA-002 in bladder cancer studyFebruary 25, 2026 | msn.comTARA-002 results send Protara shares upwardsFebruary 24, 2026 | thepharmaletter.comTProtara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 monthsFebruary 24, 2026 | fiercebiotech.comFProtara's experimental bladder cancer drug shows encouraging resultsFebruary 24, 2026 | msn.comProtara falls after mid-stage trial data for lead asset in bladder cancerFebruary 24, 2026 | msn.comProtara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer TranscriptFebruary 24, 2026 | seekingalpha.comProtara Therapeutics Shares Surge on Promising Clinical Trial DataFebruary 24, 2026 | aktiencheck.deADoes TARA stock’s 15% after-hours slump signal a bargain after new bladder cancer data?February 24, 2026 | msn.comProtara Therapeutics stock tumbles on trial data releaseFebruary 23, 2026 | za.investing.comTARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerFebruary 23, 2026 | globenewswire.comProtara Therapeutics to Participate in Upcoming Investor ConferencesFebruary 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSBR, TARA, PRLD, and NERV Company DescriptionsChampions Oncology NASDAQ:CSBR$5.98 +0.01 (+0.17%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$5.91 -0.07 (-1.15%) As of 05/6/2026 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Minerva Neurosciences NASDAQ:NERV$6.23 -0.02 (-0.32%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$6.26 +0.03 (+0.48%) As of 05/6/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Prelude Therapeutics NASDAQ:PRLD$4.84 +0.17 (+3.64%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$4.70 -0.14 (-2.79%) As of 05/6/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Protara Therapeutics NASDAQ:TARA$5.66 +0.25 (+4.62%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$5.62 -0.04 (-0.80%) As of 05/6/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
